BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 8978793)

  • 1. [Methotrexate in gynecologic oncology].
    Isonishi S; Terashima Y
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1896-900. PubMed ID: 8978793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of single-agent chemotherapy regimens for gestational trophoblastic disease.
    Homesley HD
    J Reprod Med; 1994 Mar; 39(3):185-92. PubMed ID: 7518517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of high-risk gestational trophoblastic disease with methotrexate, actinomycin D, and cyclophosphamide chemotherapy.
    Lurain JR; Brewer JI
    Obstet Gynecol; 1985 Jun; 65(6):830-6. PubMed ID: 2987766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia.
    Lurain JR; Nejad B
    Gynecol Oncol; 2005 May; 97(2):618-23. PubMed ID: 15863169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen.
    Surwit EA; Childers JM
    J Reprod Med; 1991 Jan; 36(1):45-8. PubMed ID: 1848900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of high-risk gestational trophoblastic disease.
    Lurain JR
    J Reprod Med; 1998 Jan; 43(1):44-52. PubMed ID: 9475149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
    Schink JC; Singh DK; Rademaker AW; Miller DS; Lurain JR
    Obstet Gynecol; 1992 Nov; 80(5):817-20. PubMed ID: 1328977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy.
    Lurain JR; Singh DK; Schink JC
    J Reprod Med; 2006 Oct; 51(10):767-72. PubMed ID: 17086804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate monotherapy for high-risk gestational trophoblastic neoplasia after therapy with etoposide, methotrexate, and dactinomycin: a case report.
    Taran A; Ignatov A; Smith B; Bischoff J; Costa SD
    Am J Obstet Gynecol; 2008 Nov; 199(5):e6-8. PubMed ID: 18984073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VP-16 in combinations for first-line treatment of malignant germ-cell tumors and gestational choriocarcinoma.
    Newlands ES
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):37-41. PubMed ID: 2579442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D.
    Soto-Wright V; Goldstein DP; Bernstein MR; Berkowitz RS
    Gynecol Oncol; 1997 Jan; 64(1):156-9. PubMed ID: 8995566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
    Soper JT; Evans AC; Clarke-Pearson DL; Berchuck A; Rodriguez G; Hammond CB
    Obstet Gynecol; 1994 Jan; 83(1):113-7. PubMed ID: 8272290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia.
    Kohorn EI
    Gynecol Oncol; 1993 Sep; 50(3):300-4. PubMed ID: 8406191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
    Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
    J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of drug resistant gestational trophoblastic neoplasia.
    Patel SM; Desai A
    J Reprod Med; 2010; 55(7-8):296-300. PubMed ID: 20795341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
    Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
    J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Etoposide (VP-16) in gynecologic malignancy].
    Kanazawa K; Moromizato H
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1925-8. PubMed ID: 8978799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors.
    Matsui H; Suzuka K; Iitsuka Y; Seki K; Sekiya S
    Gynecol Oncol; 2000 Jul; 78(1):28-31. PubMed ID: 10873405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placental site trophoblastic tumor: an overview.
    Bonazzi C; Urso M; Dell'Anna T; Sacco S; Buda A; CantĂș MG
    J Reprod Med; 2004 Aug; 49(8):585-8. PubMed ID: 15457847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
    Lurain JR; Schink JC
    J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.